- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HealthCare.gov Has Already Cost $840 Million
HealthCare.gov, the federal health-exchange website plagued with glitches at its launch, has already cost $840 million to build, according to a Government Accountability Office (GAO) review of two task orders and one contract related to building the system.
HealthCare.gov, the federal health-exchange website plagued with glitches at its launch, has already cost $840 million to build, according to a Government Accountability Office (GAO) review of two task orders and one contract related to building the system.
he cost overruns were incurred through a combination of inconsistent oversight and constantly changing requirements, according to testimony prepared by GAO's Director of Acquisition and Sourcing Management, William Woods, who is scheduled to testify before a House Energy and Commerce Committee subcommittee Thursday.
"We found that CMS undertook the development of HealthCare.gov and its related systems without effective planning or oversight practices, despite facing a number of challenges that increased both the level of risk and the need for effective oversight," Woods will say. "According to [Center for Medicare and Medicaid Services] program and contracting officials, the task of developing a first-of-its-kind federal marketplace was a complex effort that was exacerbated by compressed time frames and changing requirements."
Read the full story here: http://cbsn.ws/Xoj0LJ
Source: CBS News
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
